Was that labeling issue in the notes of meeting with the FDA or a misunderstanding by management?
Many factors at play here. We are now on our 3rd FDA Director dealing with SequestOx. Each has a different view of the science, data & risks. Science is sometimes more gray than black & white and this is no different. I am sure Gottlieb will want to make his mark on this one too, protecting BP, of course.